Company / Operating Income
ImmunityBio, Inc. Operating Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$256.0M
FY2025
5-year range
-$362.3M / -$156.3M
FY2021-FY2025
Trend
+25.6%
vs FY2024
Sector context
#158 of 204
Health Care
What the data says
ImmunityBio, Inc.'s operating income of -$256M is lower than 77% of companies in the Health Care sector (FY2025). Operating Income has fluctuated over the past 10 years, ranging from -$362M in FY2023 to -$6M in FY2016.
Based on SEC 10-K filings.
-$256M in FY2025.
Improved from -$362M to -$256M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 23% in Health CareTop 77% of 204This company -$256.0M Sector average $107.8M
▼
-337.6% below sector average
Key checks
Key Insights
- In FY2025, operating income increased 25.6% year-over-year.
- Ranks #158 out of 204 companies in the Health Care sector.
- Peak operating income was recorded in FY2016.
- Lowest operating income in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score -7.50 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$256.0M | +25.6% |
| FY2024 | -$344.2M | +5.0% |
| FY2023 | -$362.3M | -3.1% |
| FY2022 | -$351.3M | -124.8% |
| FY2021 | -$156.3M | +29.3% |
| FY2020 | -$220.9M | -41.4% |
| FY2019 | -$156.3M | -25.5% |
| FY2018 | -$124.5M | +47.9% |
| FY2017 | -$238.9M | -4184.8% |
| FY2016 | -$5.6M | +97.7% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026